Patent ID: 8541169
Filing Date: 2013-09-24
Classification: A61P,C12N,C12Q

Abstract:
1. A method of detecting an increased risk of prostate cancer in a human subject, comprising; (a) measuring the expression level of , ERG Prostate Cancer-specific isoform 1 (EPCI) or ERG Prostate Cancer-specific isoform 2(EPC2) in a nucleic acid sample isolated from prostate epithelial cells from the subject, wherein measuring the expression level of EPC1 or EPC2 comprises: (b) comparing the expression level of EPC1 or EPC2 in the nucleic acid sample to the expression level of EPC1 or EPC2 in a control sample comprising prostate epithelial cells or to a threshold value; and (c) correlating the expression level of EPC1 or EPC2 in the nucleic acid sample to the increased risk of prostate cancer in the subject, wherein increased expression levels of EPC1 or EPC2 in the nucleic acid sample as compared to the control sample or the threshold value indicate the increased risk of prostate cancer.